Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

cAd3-Marburg Vaccine in Healthy Adults

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT03475056
Recruitment Status : Completed
First Posted : March 23, 2018
Results First Posted : January 14, 2021
Last Update Posted : February 8, 2021
Sponsor:
Collaborator:
US Military HIV Research Program
Information provided by (Responsible Party):
National Institute of Allergy and Infectious Diseases (NIAID)

Brief Summary:
RV 507 was a Phase I, open-label study to examine the safety, tolerability and immunogenicity of an investigational Marburg vaccine given by intramuscular (IM) injection to healthy adults. The study was a dose escalation of VRC-MARADC087-00-VP, a chimpanzee adenovirus serotype 3 (cAd3) vector vaccine, which encodes wild type (WT) glycoprotein (GP) from Marburgvirus.

Condition or disease Intervention/treatment Phase
Marburg Virus Disease Biological: cAd3-Marburg vaccine Phase 1

Detailed Description:
A total of 40 participants were evenly split, with 20 in each of the two dosage groups, to receive the investigational cAd3-Marburg vaccine at a dose of either 1x10^10 particle units (PU) (Group 1) or 1x10^11 PU (Group 2). The dose escalation plan included daily review of any new safety data by a study clinician, regular review of safety data by the protocol team and a staged enrollment plan with required interim safety reviews. The study began with enrollment of 3 participants into Group 1 (1x10^10 PU) at a rate of 1 participant per day. After at least 7 days of follow-up for the first 3 vaccinated participants, an interim safety review occurred before enrollment of additional participants into the group. No safety issues were identified; therefore, an additional 17 participants were enrolled to complete Group 1. When there was a minimum of seven days of follow-up safety data from the last enrolled participant in Group 1, an interim safety review occurred. Once no safety issues were identified, enrollment of participants into the next dose level began with the enrollment of 3 participants at a rate of 1 participant per day. After at least 7 days of follow-up for the first 3 vaccinated participants in Group 2 (1x10^11 PU), an interim safety review occurred before the enrollment of additional participants into Group 2. No safety issues were identified and an additional 17 participants were enrolled to complete Group 2. Participants were followed for approximately 48 weeks.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 40 participants
Allocation: Non-Randomized
Intervention Model: Sequential Assignment
Intervention Model Description: Dose escalation
Masking: None (Open Label)
Primary Purpose: Prevention
Official Title: RV 507: A Phase I Open-Label, Dose-Escalation Clinical Trial to Evaluate the Safety, Tolerability and Immunogenicity of the Marburg Chimpanzee Adenovirus Vector Vaccine, VRC-MARADC087-00-VP (cAd3-Marburg), in Healthy Adults
Actual Study Start Date : October 9, 2018
Actual Primary Completion Date : December 19, 2019
Actual Study Completion Date : December 19, 2019

Resource links provided by the National Library of Medicine


Arm Intervention/treatment
Experimental: Group 1: cAd3-Marburg vaccine (1x10^10 PU)
cAd3-Marburg vaccine (1x10^10 PU) administered intramuscularly (IM) with needle and syringe in a volume of 1 mL
Biological: cAd3-Marburg vaccine
The recombinant chimpanzee adenovirus Type 3-vectored Marburg vaccine, VRC-MARADC087-00-VP (cAd3-Marburg) is composed of a cAd3 vector that expresses Marburg wild type glycoprotein (WT GP).
Other Name: VRC-MARADC087-00-VP

Experimental: Group 2: cAd3-Marburg vaccine (1x10^11 PU)
cAd3-Marburg vaccine (1x10^11 PU) administered IM with needle and syringe in a volume of 1 mL
Biological: cAd3-Marburg vaccine
The recombinant chimpanzee adenovirus Type 3-vectored Marburg vaccine, VRC-MARADC087-00-VP (cAd3-Marburg) is composed of a cAd3 vector that expresses Marburg wild type glycoprotein (WT GP).
Other Name: VRC-MARADC087-00-VP




Primary Outcome Measures :
  1. Number of Participants Reporting Local Reactogenicity Signs and Symptoms for 7 Days After the cAd3-Marburg Vaccine Administration [ Time Frame: 7 days after study product administration ]
    Participants recorded the occurrence of solicited symptoms on a diary card for 7 days after the study product administration and reviewed the diary card with clinic staff at a follow up visit. Participants were counted once for each symptom at the worst severity if they indicated experiencing the symptom more than one time at any severity during the reporting period. The number reported for "Any Local Symptom" is the number of participants reporting any local symptom at the worst severity. Reactogenicity grading (Mild, Moderate, Severe) was done using the Toxicity Grading Scale for Healthy Adult and Adolescent Volunteers Enrolled in Preventive Vaccine Clinical Trials (FDA Guidance - September 2007).

  2. Number of Participants Reporting Systemic Reactogenicity Signs and Symptoms for 7 Days After the cAd3-Marburg Vaccine Administration [ Time Frame: 7 days after study product administration ]
    Participants recorded the occurrence of solicited symptoms on a diary card for 7 days after the study product administration and reviewed the diary card with clinic staff at a follow up visit. Participants were counted once for each symptom at the worst severity if they indicated experiencing the symptom more than one time at any severity during the reporting period. The number reported for "Any Systemic Symptom" is the number of participants reporting any systemic symptom at the worst severity. The majority of the reactogenicity grading (Mild, Moderate, Severe) was done using the Toxicity Grading Scale for Healthy Adult and Adolescent Volunteers Enrolled in Preventive Vaccine Clinical Trials (FDA Guidance - September 2007).The Division of AIDS AE Grading Table Corrected (Version 2.1-July 2017) was used to grade reported events of joint pain (arthralgia).

  3. Total Number of Participants Reporting Any Reactogenicity Signs and Symptoms for 7 Days After the cAd3-Marburg Vaccine Administration [ Time Frame: 7 days after study product administration ]
    Participants recorded the occurrence of solicited symptoms on a diary card for 7 days after the study product administration.

  4. Number of Participants With Abnormal Laboratory Measures of Safety [ Time Frame: Through 48 weeks after study product administration ]
    Any abnormal laboratory results recorded as unsolicited AEs are summarized. Labs included hematology (hemoglobin, hemoglobin change from baseline, hematocrit percent, mean corpuscular volume (MCV), platelets, and white blood cell (WBC), red blood cell (RBC) and lymphocyte counts) and chemistry (alanine aminotransferase (ALT) and creatinine). Complete blood count (CBC) with total lymphocyte count results were collected at screening (≤ 56 days before enrollment), Day 0 prior to study product administration (baseline), Day 3, and Weeks 2, 4, 8 and 24. Creatinine and ALT results were collected at screening, Day 0, Day 3 and Weeks 2, 4 and 8. Institutional laboratory normal ranges as well as the Toxicity Grading Scale for Healthy Adult and Adolescent Volunteers Enrolled in Preventative Vaccine Clinical Trials FDA Guidance, September 2007 were used.

  5. Number of Participants With One or More Unsolicited Non-Serious Adverse Events (AEs) [ Time Frame: Through 28 days after study product administration ]
    Unsolicited AEs and attribution assessments were recorded in the study database from receipt of the study product administration through the visit scheduled for 28 days after study product administration. At other time periods greater than 28 days after the study product administration, only serious AEs (SAEs reported as a separate outcome and in the AE module), and new chronic medical conditions that required ongoing medical management were recorded through the last study visit. The relationship between an AE and the study product was assessed by the investigator based on clinical judgment and the definitions outlined in the protocol. A participant with multiple experiences of the same event is counted once using the event of worst severity.

  6. Number of Participants With Serious Adverse Events (SAEs) [ Time Frame: Through 48 weeks after study product administration ]
    SAEs were recorded from receipt of the study product administration through the last expected study visit at Week 48. The relationship between a SAE and the study product was assessed by the investigator based on clinical judgment and the definitions outlined in the protocol. A participant with multiple experiences of the same event is counted once using the event of worst severity.


Secondary Outcome Measures :
  1. Mean Titers of Antibodies to the Recombinant Chimpanzee Adenovirus Serotype 3 (cAd3) Vector at 28 Days After the cAd3-Marburg Vaccine Administration [ Time Frame: Through 28 days after study product administration ]
    Vaccine-induced, cAd3-specific antibody responses as measured by neutralization assay. Participant blood samples were tested for cAd3-specific neutralizing activity, prior to and following vaccination, using a luciferase reporter gene virus neutralization assay as previously described (Clin Vaccine Immunol 2014; 21:783-6, References Section).

  2. Mean Titers of Antibodies to the Human Adenovirus Serotype 5 (Ad5) Vector at 28 Days After the cAd3-Marburg Vaccine Administration [ Time Frame: Through 28 days after study product administration ]
    Vaccine-induced, Ad5-specific antibody responses as measured by neutralization assay. Participant blood samples were tested for Ad5-specific neutralizing activity, prior to and following vaccination, using a luciferase reporter gene virus neutralization assay as previously described (Clin Vaccine Immunol 2014; 21:783-6, References Section).

  3. Percentage of Participants With a Positive Marburg-Specific Antibody Response After the cAd3-Marburg Vaccine Administration [ Time Frame: Through 28 days after study product administration ]
    A positive response occurs if there is a significant increase in the ELISA post vaccination compared to baseline. For each participant, a t-test was performed to compare the post vaccination titers versus those at baseline. A participant is defined as a positive responder if the one-sided t-test has a p-value < 0.05.

  4. Magnitude of Marburg-Specific Antibody Responses After the cAd3-Marburg Vaccine Administration [ Time Frame: Through 28 days after study product administration ]
    Geometric mean titer (GMT) was calculated along with 95% confidence intervals at Week 4 for each dose group.

  5. Percentage of Participants With Positive Marburg-specific T Cell Responses After the cAd3-Marburg Vaccine Administration [ Time Frame: Through 28 days after study product administration ]
    T cell response was measured by Intracellular Cytokine Staining (ICS) assays using Peripheral Blood Mononuclear Cells (PBMCs) at 4 weeks after vaccination. The percentage of participants with T cell responses with Clopper-Pearson 95% Confidence Intervals are presented. Positivity is defined as a response over calculated thresholds determined by the trial statistician.

  6. Magnitude of Marburg-specific T Cell Responses After the cAd3-Marburg Vaccine Administration [ Time Frame: Through 28 days after study product administration ]
    Median and interquartile ranges presented for total cytokine responses for both CD4 and CD8 memory T cells based on a T cell response with any cytokine at Week 4 for each dose group.



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years to 50 Years   (Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes
Criteria

Inclusion Criteria:

  1. 18 to 50 years old
  2. Available for clinical follow-up through Week 48 after enrollment
  3. Able to provide proof of identity to the satisfaction of the study clinician completing the enrollment process. Proof of identity includes a valid U.S. government-issued or state-issued photo identification (ID) such as a driver's license, military ID, or U.S. passport.
  4. Able and willing to provide a personal mobile phone number or home phone number at which the participant can be reliably contacted. Participants will be contacted primarily for study visit 2A (Appendix 1), as a reminder of an upcoming visit, and after missed visits for rescheduling purposes.
  5. Able and willing to complete the informed consent process and demonstrate understanding with a passing score (90% or greater) on the Assessment of Understanding (AOU) by the third attempt.
  6. In good general health without clinically significant medical history.
  7. Physical examination and laboratory results without clinically significant findings and a body mass index (BMI) ≤ 40 within the 56 days prior to enrollment.
  8. Laboratory Criteria within 56 days prior to enrollment:

    1. Hemoglobin ≥ 11.5 g/dL for women; ≥13.0 g/dL for men.
    2. White blood cells (WBC) = 3,300-12,000 cells/mm^3.
    3. Total lymphocyte count ≥ 800 cells/mm^3.
    4. Platelets = 125,000 - 400,000/mm^3.
    5. Alanine aminotransferase (ALT) ≤ 1.25 x upper limit of normal.
    6. Serum creatinine ≤ 1 x upper limit of normal.
    7. HIV-uninfected as evidenced by a negative FDA-approved HIV diagnostic blood test.

    Female-Specific Criteria:

  9. Negative β-HCG (human chorionic gonadotropin) pregnancy test; serum β-HCG at screening (or urine if screening is the same day as enrollment) and urine β-HCG at enrollment if woman is of reproductive potential.
  10. Agrees to use an effective means of birth control from at least 21 days prior to enrollment through 24 weeks after study vaccination if assessed to be of reproductive potential.

Exclusion Criteria:

Volunteer has received any of the following substances:

  1. Investigational Ebola or Marburg vaccine in a prior clinical trial or prior receipt of a cAd3 vectored investigational vaccine.
  2. Immunosuppressive medications within 2 weeks prior to enrollment.
  3. Blood products within 112 days (16 weeks) prior to enrollment.
  4. Investigational research agents within 28 days (4 weeks) prior to enrollment.
  5. Live attenuated vaccines within 28 days (4 weeks) prior to enrollment.
  6. Subunit or killed vaccines within 14 days (2 weeks) prior to enrollment.
  7. Current anti-tuberculosis prophylaxis or therapy.

    Female-specific criteria:

  8. Woman who is pregnant, breast-feeding or planning to become pregnant during the first 24 weeks after study vaccine administration.

    Volunteer has a history of any of the following clinically significant conditions:

  9. Serious adverse reactions to vaccines such as anaphylaxis, urticaria (hives), respiratory difficulty, angioedema, or abdominal pain.
  10. Allergic reaction to excipients in the study vaccine including gentamycin, neomycin or streptomycin.
  11. Clinically significant autoimmune disease or immunodeficiency.
  12. Asthma that is not well controlled.
  13. Positive syphilis serology. False-positive results will also exclude a participant.
  14. Diabetes mellitus (type I or II).
  15. Thyroid disease that is not well controlled.
  16. A history of hereditary angioedema (HAE), acquired angioedema (AAE), or idiopathic forms of angioedema.
  17. Idiopathic urticaria within the last 1 year.
  18. Hypertension that is not well controlled.
  19. Bleeding disorder diagnosed by a doctor (e.g. factor deficiency, coagulopathy, or platelet disorder requiring special precautions) or significant bruising or bleeding difficulties with intramuscular (IM) injections or blood draws.
  20. A malignancy that is active, currently being treated, or not surgically cured.
  21. Seizure in the past 3 years or treatment for seizure disorder in the past 3 years.
  22. Asplenia or functional asplenia.
  23. Psychiatric condition that precludes compliance with the protocol; past or present psychoses; or within five years prior to enrollment, history of a suicide plan or attempt.
  24. Any medical, psychiatric, social condition, occupational reason or other responsibility that, in the judgment of the investigator, is a contraindication to protocol participation or impairs a volunteer's ability to give informed consent.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03475056


Locations
Layout table for location information
United States, Maryland
WRAIR Clinical Trials Center,
Silver Spring, Maryland, United States, 20910
Sponsors and Collaborators
National Institute of Allergy and Infectious Diseases (NIAID)
US Military HIV Research Program
Investigators
Layout table for investigator information
Principal Investigator: Melinda Hamer, M.D. WRAIR Clinical Trials Center
  Study Documents (Full-Text)

Documents provided by National Institute of Allergy and Infectious Diseases (NIAID):
Publications:

Layout table for additonal information
Responsible Party: National Institute of Allergy and Infectious Diseases (NIAID)
ClinicalTrials.gov Identifier: NCT03475056    
Other Study ID Numbers: RV 507
WRAIR #2438 ( Other Identifier: WRAIR )
First Posted: March 23, 2018    Key Record Dates
Results First Posted: January 14, 2021
Last Update Posted: February 8, 2021
Last Verified: January 2021
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: No
Keywords provided by National Institute of Allergy and Infectious Diseases (NIAID):
Marburg virus
Marburg vaccine
cAd3-Marburg vaccine
Additional relevant MeSH terms:
Layout table for MeSH terms
Virus Diseases
Marburg Virus Disease
Infections
Hemorrhagic Fevers, Viral
RNA Virus Infections
Filoviridae Infections
Mononegavirales Infections